These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 37405738)

  • 21. Azacitidine for patients with Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic syndrome (VEXAS) and myelodysplastic syndrome: data from the French VEXAS registry.
    Comont T; Heiblig M; Rivière E; Terriou L; Rossignol J; Bouscary D; Rieu V; Le Guenno G; Mathian A; Aouba A; Vinit J; Dion J; Kosmider O; Terrier B; Georgin-Lavialle S; Fenaux P; Mekinian A;
    Br J Haematol; 2022 Feb; 196(4):969-974. PubMed ID: 34651299
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Successful azacitidine therapy for myelodysplastic syndrome associated with VEXAS syndrome.
    Kataoka A; Mizumoto C; Kanda J; Iwasaki M; Sakurada M; Oka T; Fujimoto M; Yamamoto Y; Yamashita K; Nannya Y; Ogawa S; Takaori-Kondo A
    Int J Hematol; 2023 Jun; 117(6):919-924. PubMed ID: 36641501
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recurrent superior orbital fissure syndrome associated with VEXAS syndrome.
    Myint K; Patrao N; Vonica O; Vahdani K
    J Ophthalmic Inflamm Infect; 2023 Sep; 13(1):39. PubMed ID: 37673972
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recurrent orbital inflammation associated with VEXAS syndrome.
    Beecher MB; Tong JY; Halliday LA; Hissaria P; Selva D
    Orbit; 2024 Jun; 43(3):350-353. PubMed ID: 36168114
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Case Report: Genetic Double Strike: VEXAS and TET2-Positive Myelodysplastic Syndrome in a Patient With Long-Standing Refractory Autoinflammatory Disease.
    Lötscher F; Seitz L; Simeunovic H; Sarbu AC; Porret NA; Feldmeyer L; Borradori L; Bonadies N; Maurer B
    Front Immunol; 2021; 12():800149. PubMed ID: 35126364
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Somatic Mutations in
    Beck DB; Ferrada MA; Sikora KA; Ombrello AK; Collins JC; Pei W; Balanda N; Ross DL; Ospina Cardona D; Wu Z; Patel B; Manthiram K; Groarke EM; Gutierrez-Rodrigues F; Hoffmann P; Rosenzweig S; Nakabo S; Dillon LW; Hourigan CS; Tsai WL; Gupta S; Carmona-Rivera C; Asmar AJ; Xu L; Oda H; Goodspeed W; Barron KS; Nehrebecky M; Jones A; Laird RS; Deuitch N; Rowczenio D; Rominger E; Wells KV; Lee CR; Wang W; Trick M; Mullikin J; Wigerblad G; Brooks S; Dell'Orso S; Deng Z; Chae JJ; Dulau-Florea A; Malicdan MCV; Novacic D; Colbert RA; Kaplan MJ; Gadina M; Savic S; Lachmann HJ; Abu-Asab M; Solomon BD; Retterer K; Gahl WA; Burgess SM; Aksentijevich I; Young NS; Calvo KR; Werner A; Kastner DL; Grayson PC
    N Engl J Med; 2020 Dec; 383(27):2628-2638. PubMed ID: 33108101
    [TBL] [Abstract][Full Text] [Related]  

  • 27. VEXAS syndrome with progression of MDS to MDS/MPN overlap syndrome.
    Neupane K; Jayarangaiah A; Zhang Y; Kumar A
    BMJ Case Rep; 2022 Dec; 15(12):. PubMed ID: 36549759
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Somatic Mutations in UBA1 Define a Distinct Subset of Relapsing Polychondritis Patients With VEXAS.
    Ferrada MA; Sikora KA; Luo Y; Wells KV; Patel B; Groarke EM; Ospina Cardona D; Rominger E; Hoffmann P; Le MT; Deng Z; Quinn KA; Rose E; Tsai WL; Wigerblad G; Goodspeed W; Jones A; Wilson L; Schnappauf O; Laird RS; Kim J; Allen C; Sirajuddin A; Chen M; Gadina M; Calvo KR; Kaplan MJ; Colbert RA; Aksentijevich I; Young NS; Savic S; Kastner DL; Ombrello AK; Beck DB; Grayson PC
    Arthritis Rheumatol; 2021 Oct; 73(10):1886-1895. PubMed ID: 33779074
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The VEXAS Syndrome: Uncontrolled Inflammation and Macrocytic Anaemia in a 77-Year-Old Male Patient.
    Himmelmann A; Brücker R
    Eur J Case Rep Intern Med; 2021; 8(4):002484. PubMed ID: 33987129
    [TBL] [Abstract][Full Text] [Related]  

  • 30. VEXAS Syndrome: A Novelty in MDS Landscape.
    Templé M; Kosmider O
    Diagnostics (Basel); 2022 Jun; 12(7):. PubMed ID: 35885496
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [VEXAS syndrome].
    Zeeck M; Kötter I; Krusche M
    Z Rheumatol; 2022 Nov; 81(9):782-786. PubMed ID: 35179640
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An update on VEXAS syndrome.
    Al-Hakim A; Savic S
    Expert Rev Clin Immunol; 2023 Feb; 19(2):203-215. PubMed ID: 36537591
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Benign and malignant hematologic manifestations in patients with VEXAS syndrome due to somatic mutations in UBA1.
    Obiorah IE; Patel BA; Groarke EM; Wang W; Trick M; Ombrello AK; Ferrada MA; Wu Z; Gutierrez-Rodrigues F; Lotter J; Wilson L; Hoffmann P; Cardona DO; Patel N; Dulau-Florea A; Kastner DL; Grayson PC; Beck DB; Young NS; Calvo KR
    Blood Adv; 2021 Aug; 5(16):3203-3215. PubMed ID: 34427584
    [TBL] [Abstract][Full Text] [Related]  

  • 34. VEXAS syndrome: An update.
    Khitri MY; Hadjadj J; Mekinian A; Jachiet V
    Joint Bone Spine; 2024 Jul; 91(4):105700. PubMed ID: 38307404
    [TBL] [Abstract][Full Text] [Related]  

  • 35. VEXAS within the spectrum of rheumatologic disease.
    Koster MJ; Warrington KJ
    Semin Hematol; 2021 Oct; 58(4):218-225. PubMed ID: 34802543
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vacuoles in bone marrow progenitors: VEXAS syndrome and beyond.
    Lacombe V; Hadjadj J; Georgin-Lavialle S; Lavigne C; Geneviève F; Kosmider O
    Lancet Haematol; 2024 Feb; 11(2):e160-e167. PubMed ID: 38302223
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Thrombotic manifestations of VEXAS syndrome.
    Groarke EM; Dulau-Florea AE; Kanthi Y
    Semin Hematol; 2021 Oct; 58(4):230-238. PubMed ID: 34802545
    [TBL] [Abstract][Full Text] [Related]  

  • 38. VEXAS syndrome: A dermatological perspective.
    Nguyen JK; Routledge D; van Der Weyden C; Blombery P; Angel CM; Johnson D; Goh MS; Lee A
    Australas J Dermatol; 2022 Nov; 63(4):488-492. PubMed ID: 36197697
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Further characterization of clinical and laboratory features in VEXAS syndrome: large-scale analysis of a multicentre case series of 116 French patients.
    Georgin-Lavialle S; Terrier B; Guedon AF; Heiblig M; Comont T; Lazaro E; Lacombe V; Terriou L; Ardois S; Bouaziz JD; Mathian A; Le Guenno G; Aouba A; Outh R; Meyer A; Roux-Sauvat M; Ebbo M; Zhao LP; Bigot A; Jamilloux Y; Guillotin V; Flamarion E; Henneton P; Vial G; Jachiet V; Rossignol J; Vinzio S; Weitten T; Vinit J; Deligny C; Humbert S; Samson M; Magy-Bertrand N; Moulinet T; Bourguiba R; Hanslik T; Bachmeyer C; Sebert M; Kostine M; Bienvenu B; Biscay P; Liozon E; Sailler L; Chasset F; Audemard-Verger A; Duroyon E; Sarrabay G; Borlot F; Dieval C; Cluzeau T; Marianetti P; Lobbes H; Boursier G; Gerfaud-Valentin M; Jeannel J; Servettaz A; Audia S; Larue M; Henriot B; Faucher B; Graveleau J; de Sainte Marie B; Galland J; Bouillet L; Arnaud C; Ades L; Carrat F; Hirsch P; Fenaux P; Fain O; Sujobert P; Kosmider O; Mekinian A; ;
    Br J Dermatol; 2022 Mar; 186(3):564-574. PubMed ID: 34632574
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Allogeneic stem cell transplantation as a curative therapeutic approach for VEXAS syndrome: a case report.
    Loschi M; Roux C; Sudaka I; Ferrero-Vacher C; Marceau-Renaut A; Duployez N; Passeron T; Cluzeau T
    Bone Marrow Transplant; 2022 Feb; 57(2):315-318. PubMed ID: 34999727
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.